The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence
Open accessAbstract
PROBLEM: Tumor recurrence is a major clinical issue that represents the principal cause of cancer-related deaths, with few targetable common pathways. Mechanisms by which residual tumors persist and progress under a continuous shift between hypoxia-reoxygenation after neoadjuvent-therapy are unknown. In this study, we investigated the role of lipid metabolism and tumor redox balance in tumor recurrence. METHODS: Lipidomics, proteomics and mass spectrometry imaging approaches where applied to mouse tumor models of recurrence. Genetic and pharmacological inhibitions of lipid mediators in tumors were used in vivo and in functional assays in vitro. RESULTS: We found that stearoyl-CoA desaturase-1 (SCD1) expressed by cancer cells and fatty acid binding protein-4 (FABP4) produced by tumor endothelial cells (TECs) and adipocytes in the tumor microenvironment (TME) are essential for tumor relapse in response to tyrosine kinase inhibitors (TKI) and chemotherapy. SCD1 and FABP4 were also found upregulated in recurrent human breast cancer samples and correlated with worse prognosis of cancer patients with different types of tumors. Mechanistically, SCD1 leads to fatty acid (FA) desaturation and FABP4 derived from TEM enhances lipid droplet (LD) in cancer cells, which cooperatively protect from oxidative stress-induced ferroptosis. We revealed that lipid mobilization and desaturation elicit tumor intrinsic antioxidant and anti-ferroptotic resources for survival and regrowth in a harsh TME. Inhibition of lipid transport from TME by FABP4 inhibitor reduced tumor regrowth and by genetic - or by pharmacological - targeting SCD1 in vivo, tumor regrowth was abolished completely. CONCLUSION: This finding unveils that it is worth taking advantage of tumor lipid addiction, as a tumor vulnerability to design novel treatment strategy to prevent cancer recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460 · cited 1×
“overwhelms the existing vessels and causes tumor hypoxia [35], anticancer drugs can exacerbate tumor hypoxia, which can driver drug resistance [36,37].”
BackgroundRetractedFerroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Regulation of Ferroptotic Cancer Cell Death by GPX4
Yang, W. S., SriRamaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014) · Cell · doi:10.1016/j.cell.2013.12.010 · Cited by 7,713
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Though, small-molecule FASN inhibitors (C75 and GSK837149A) have shown promising results in preclinical models [42], but these compounds failed to show efficacy as clinical tools, due to severe toxicities [43].”
BackgroundExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“Altered redox balance and redox signaling are implicated in genomic instability, tumor metabolism reprogramming [8,9], malignant progression and resistance to treat-”
BackgroundPeroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis
Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., & Stockwell, B. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603244113 · Cited by 2,329
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Cellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Energy-stress-mediated AMPK activation inhibits ferroptosis
Lee, H., Zandkarimi, F., Zhang, Y., Meena, J. K., Kim, J., Zhuang, L., Tyagi, S., Ma, L., Westbrook, T. F., Steinberg, G. R., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0461-8 · Cited by 1,128
Yi, J., Zhu, J., Wu, J., Thompson, C. B., & Jiang, X. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017152117 · Cited by 974
How cancer metabolism is tuned for proliferation and vulnerable to disruption
Schulze, A., & Harris, A. L. (2012) · Nature · doi:10.1038/nature11706 · Cited by 929
Schug, Z. T., Peck, B., Jones, D. T., Zhang, Q., Grosskurth, S., Alam, I. S., Goodwin, L. M., Smethurst, E., Mason, S., Blyth, K., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.002 · Cited by 820
Metabolic functions of FABPs—mechanisms and therapeutic implications
Hotamisligil, G. S., & Bernlohr, D. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.122 · Cited by 712
Bensaad, K., Favaro, E., Lewis, C. A., Peck, B., Lord, S., Collins, J. M., Pinnick, K. E., Wigfield, S., Buffa, F. M., Li, J.-L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.056 · Cited by 665
The Two Faces of Reactive Oxygen Species in Cancer
Reczek, C. R., & Chandel, N. S. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041916-065808 · Cited by 602
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment
Ackerman, D., & Simon, M. C. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.06.001 · Cited by 495
Hallmarks of Endothelial Cell Metabolism in Health and Disease
Li, X., Sun, X., & Carmeliet, P. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.011 · Cited by 453
Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia
Ye, J., Fan, J., Venneti, S., Wan, Y.-W., Pawel, B. R., Zhang, J., Finley, L. W. S., Lu, C., Lindsten, T., Cross, J. R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0250 · Cited by 452
Lipid signalling enforces functional specialization of Treg cells in tumours
Lim, S. A., Wei, J., Nguyen, T.-L. M., Shi, H., Su, W., Palacios, G., Dhungana, Y., Chapman, N. M., Long, L., Saravia, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03235-6 · Cited by 426
Heterogeneity of tumor-induced gene expression changes in the human metabolic network
Hu, J., Locasale, J. W., Bielas, J. H., O'Sullivan, J., Sheahan, K., Cantley, L. C., Heiden, M. G. V., & Vitkup, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2530 · Cited by 407
Semenza, G. L. (2017) · The EMBO Journal · doi:10.15252/embj.201695204 · Cited by 366
Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress
Cheng, X., Geng, F., Pan, M., Wu, X., Zhong, Y., Wang, C., Tian, Z., Cheng, C., Zhang, R., Puduvalli, V., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.002 · Cited by 347
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
Mahvi, D. A., Liu, R., Grinstaff, M. W., Colson, Y. L., & Raut, C. P. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21498 · Cited by 338
Corbet, C., Pinto, A., Martherus, R., Santiago de Jesus, J. P., Polet, F., & Feron, O. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.003 · Cited by 336
Molecular Pathways: Fatty Acid Synthase
Jones, S. F., & Infante, J. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0126 · Cited by 306
Metabolic Pathway Alterations that Support Cell Proliferation
Vander Heiden, M. G., Lunt, S. Y., Dayton, T. L., Fiske, B. P., Israelsen, W. J., Mattaini, K. R., Vokes, N. I., Stephanopoulos, G., Cantley, L. C., Metallo, C. M., et al. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.010900 · Cited by 301
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
Iwamoto, H., Abe, M., Yang, Y., Cui, D., Seki, T., Nakamura, M., Hosaka, K., Lim, S., Wu, J., He, X., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.005 · Cited by 300
Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299
Fanning, S., Haque, A., Imberdis, T., Baru, V., Barrasa, M. I., Nuber, S., Termine, D., Ramalingam, N., Ho, G. P. H., Noble, T., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.028 · Cited by 285
FABP4 as a key determinant of metastatic potential of ovarian cancer
Gharpure, K. M., Pradeep, S., Sans, M., Rupaimoole, R., Ivan, C., Wu, S. Y., Bayraktar, E., Nagaraja, A. S., Mangala, L. S., Zhang, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04987-y · Cited by 210
Metabolic and hypoxic adaptation to anti‐angiogenic therapy: a target for induced essentiality
McIntyre, A., & Harris, A. L. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404271 · Cited by 185
Krüger, A., Grüning, N.-M., Wamelink, M. M. C., Kerick, M., Kirpy, A., Parkhomchuk, D., Bluemlein, K., Schweiger, M.-R., Soldatov, A., Lehrach, H., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3797 · Cited by 183
The Pervasive Presence of Fluctuating Oxygenation in Tumors
Cárdenas-Navia, L. I., Mace, D., Richardson, R. A., Wilson, D. F., Shan, S., & Dewhirst, M. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6387 · Cited by 176
Li, F., Han, X., Li, F., Wang, R., Wang, H., Gao, Y., Wang, X., Fang, Z., Zhang, W., Yao, S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.001 · Cited by 169
Sounni, N. E., Cimino, J., Blacher, S., Primac, I., Truong, A., Mazzucchelli, G., Paye, A., Calligaris, D., Debois, D., De Tullio, P., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.022 · Cited by 169
Self-citationThe redox biology network in cancer pathophysiology and therapeutics
Manda, G., Isvoranu, G., Comanescu, M. V., Manea, A., BÜTÜNER, B. D., & Korkmaz, K. (2015) · Redox Biology · doi:10.1016/j.redox.2015.06.014 · Cited by 146
Tumour microenvironment factors shaping the cancer metabolism landscape
Anastasiou, D. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.412 · Cited by 144
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review
Floresta, G., Pistarà, V., Amata, E., Dichiara, M., Marrazzo, A., Prezzavento, O., & Rescifina, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.022 · Cited by 119
Yamashita, Y., Nishiumi, S., Kono, S., Takao, S., Azuma, T., & Yoshida, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3554-4 · Cited by 86
Self-citationHypoxia‐induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro
Sanna, K., & Rofstad, E. K. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580219 · Cited by 84
Zhang, C., Cao, S., Toole, B. P., & Xu, Y. (2014) · International Journal of Cancer · doi:10.1002/ijc.28975 · Cited by 70
Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy
Curtarello, M., Tognon, M., Venturoli, C., Silic‐Benussi, M., Grassi, A., Verza, M., Minuzzo, S. A., Pinazza, M., Brillo, V., Tosi, G., et al. (2019) · Cells · doi:10.3390/cells8121601 · Cited by 39
Self-citationBrain Region-Specific Dynamics of On-Tissue Protein Digestion Using MALDI Mass Spectrometry Imaging
Heijs, B., Tolner, E. A., Bovée, J. V. M. G., van den Maagdenberg, A. M. J. M., & McDonnell, L. A. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00849 · Cited by 30
Cited by
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
Targeting ROS in cancer: rationale and strategies
Glorieux, C., Liu, S., Trachootham, D., & Huang, P. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00979-4 · Cited by 651
The role of lipids in cancer progression and metastasis
Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.023 · Cited by 563
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Metadata
- Authors
- Luis, G., Godfroid, A., Nishiumi, S., Cimino, J., Blacher, S., Maquoi, E., Wery, C., Collignon, A., Longuespée, R., Montero-Ruiz, L., Dassoul, I., Maloujahmoum, N., Pottier, C., Mazzucchelli, G., Depauw, E., Bellahcène, A., Yoshida, M., Noel, A., & Sounni, N. E.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 43
- Pages
- 102006
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W3160339144
- Cited by
- 286
- References
- 47
- FWCI
- 13.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.